----
Current ValuationThe current P/E ratio is -18.52, within the reasonable range, cheaper than 63.68% of the time in the past 3 years, and the industry ranks 21/27, the industry Median 47.37.
-18.52xP/E
¥6.25Stock price
¥-0.34Earnings per share
-18.52xP/E
Stock price¥6.25Earnings per share¥-0.34
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -16.44x
- Typical range
- -24.77x–-14.40x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 47.37x
012243648
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 47.37x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
300347SZTigermed | -104.98x | 45.30% | ¥42.47B |
688114SHMGI | -116.51x | 70.26% | ¥22.11B |
688202SHMedicilon | -222.50x | -- | ¥10.27B |
688068SHHotgen | -20.76x | -- | ¥6.21B |
603108SHRunda Medical | -9.91x | 137.36% | ¥5.54B |
300463SZmaccura | -165.16x | 369.81% | ¥5.43B |
301096SZBio-S | -26.40x | -- | ¥4.70B |
688238SHOBiO Tech | -18.52x | 18.92% | ¥4.06B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
